Sugi Predict

Sugi Predict / Targets / MAGI3

MAGI3

Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 · Q5TCQ9 · MAGI3 on Sugi Atlas →

1,264 patent compounds predicted against MAGI3, 1,034 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9069771 SCHEMBL9069771 0.77 1/20
SCHEMBL7392686 SCHEMBL7392686 0.72 1/20
SCHEMBL7392689 SCHEMBL7392689 0.72 1/20
SCHEMBL20504632 SCHEMBL20504632 0.70 1/20
SCHEMBL20504633 SCHEMBL20504633 0.70 1/20
SCHEMBL21360941 SCHEMBL21360941 0.70 1/20
SCHEMBL7400882 SCHEMBL7400882 0.70 1/20
SCHEMBL9114908 SCHEMBL9114908 0.69 1/20
SCHEMBL9114918 SCHEMBL9114918 0.69 1/20
SCHEMBL9141706 SCHEMBL9141706 0.69 1/20
SCHEMBL9141715 SCHEMBL9141715 0.69 1/20
SCHEMBL9069988 SCHEMBL9069988 0.69 1/20
SCHEMBL9069770 SCHEMBL9069770 0.68 1/20
SCHEMBL7401384 SCHEMBL7401384 0.68 1/20
SCHEMBL7401386 SCHEMBL7401386 0.68 1/20
SCHEMBL29449894 SCHEMBL29449894 0.67 1/20
SCHEMBL30000971 SCHEMBL30000971 0.66 1/20
SCHEMBL7400066 SCHEMBL7400066 0.66 1/20
SCHEMBL7400067 SCHEMBL7400067 0.66 1/20
SCHEMBL7442640 SCHEMBL7442640 0.66 1/20

Clinical trials — most relevant to MAGI3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Fingolimod in Schizophrenia Patients PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE PHASE2UNKNOWN
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma PHASE1COMPLETED
Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis EARLY_PHASE1RECRUITING
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL EARLY_PHASE1UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Immune Cell Response to Stimuli nanRECRUITING
OEA for Targeting Lipid Metabolism in GWI nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Role of Nox2 in CNI-induced Renal Fibrosis nanCOMPLETED
The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory nanCOMPLETED
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle? nanUNKNOWN
Study of Metabolic Modifications in Children With Noonan Syndrome nanCOMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms nanCOMPLETED
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN) nanRECRUITING
Effect of Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients nanNOT_YET_RECRUITING
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia nanRECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAGI3 binder may also engage these)

ProteinNameSimilarity
Q9EQJ9 — 1.000 Q9EQJ9 →
Q5F488 — 1.000 Q5F488 →
A1A5G4 — 1.000 A1A5G4 →
Q9JK71 — 0.998 Q9JK71 →
Q96QZ7 — 0.989 Q96QZ7 →
Q4L1J4 — 0.988 Q4L1J4 →
Q8TEW0 — 0.987 Q8TEW0 →
Q8TEW8 — 0.987 Q8TEW8 →
Q6RHR9 — 0.984 Q6RHR9 →
Q925T6 — 0.984 Q925T6 →
Q9ULJ8 — 0.983 Q9ULJ8 →
Q8TDW5 — 0.983 Q8TDW5 →
P97879 — 0.983 P97879 →
Q6ZWJ1 — 0.983 Q6ZWJ1 →
Q9QZR8 — 0.983 Q9QZR8 →
Q812E4 — 0.983 Q812E4 →
O15018 — 0.982 O15018 →
Q9CSB4 — 0.982 Q9CSB4 →
Q8BMA3 — 0.982 Q8BMA3 →
Q99NH2 — 0.982 Q99NH2 →
Q99469 — 0.982 Q99469 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.982 landscape →
Q4V8Y7 — 0.982 Q4V8Y7 →
Q9UPX8 — 0.982 Q9UPX8 →
P34152 — 0.981 P34152 →
Q9WV89 — 0.981 Q9WV89 →
F1MAD2 — 0.981 F1MAD2 →
Q8C0D4 — 0.981 Q8C0D4 →
Q6DD51 — 0.981 Q6DD51 →
Q9H694 — 0.981 Q9H694 →